var data={"title":"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/contributors\" class=\"contributor contributor_credentials\">Jennifer Ang Chan, MD, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/contributors\" class=\"contributor contributor_credentials\">Matthew Kulke, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/contributors\" class=\"contributor contributor_credentials\">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 19, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H190948900\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuroendocrine cells are distributed widely throughout the body, and neoplasms of these cells, which are termed neuroendocrine tumors (NETs), can arise at many sites. The classification and nomenclature of NETs arising within the digestive system (gastroenteropancreatic NETs) have evolved over the past two decades (see <a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system#H799311\" class=\"medical medical_review\">&quot;Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system&quot;, section on 'Classification and terminology'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Well-differentiated NETs show a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm (<a href=\"image.htm?imageKey=ONC%2F74630\" class=\"graphic graphic_picture graphicRef74630 \">picture 1</a>). These tumors were traditionally referred to as carcinoid tumors when they arose in the tubular gastrointestinal tract and pancreatic neuroendocrine (islet cell) tumors when they arose in the pancreas or, in the case of gastrinomas, in the proximal portion of the duodenum. (See <a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system#H799304\" class=\"medical medical_review\">&quot;Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system&quot;, section on 'Morphology and immunohistochemistry'</a> and <a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis#H11\" class=\"medical medical_review\">&quot;Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis&quot;, section on 'Tumor localization'</a>.)</p><p/><p class=\"bulletIndent1\">Although gastrointestinal and pancreatic NETs are morphologically similar on routine histologic evaluation, they differ in terms of pathogenesis, biology, and response to therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Poorly-differentiated neuroendocrine tumors, which are called neuroendocrine carcinomas, are high-grade carcinomas that can resemble and have a clinical behavior similar to small cell or large cell neuroendocrine carcinoma of the lung (<a href=\"image.htm?imageKey=ONC%2F74630\" class=\"graphic graphic_picture graphicRef74630 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system#H440387068\" class=\"medical medical_review\">&quot;Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system&quot;, section on 'Pathology, tumor classification, and nomenclature'</a> and <a href=\"topic.htm?path=high-grade-gastroenteropancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;High-grade gastroenteropancreatic neuroendocrine neoplasms&quot;</a>.)</p><p/><p>Systemic treatment options to control tumor growth and symptoms related to hormone hypersecretion for patients with advanced or metastatic well-differentiated NETs arising in the gastrointestinal tract (gastrointestinal neuroendocrine tumors [GINETs], carcinoid tumors) will be discussed in this topic review. Systemic therapy options for pancreatic neuroendocrine tumors and for poorly-differentiated neuroendocrine carcinomas arising in the digestive tract are discussed elsewhere, as are local management options for well-differentiated metastatic gastroenteropancreatic NETs; the clinical presentation, imaging, and biochemical monitoring; pathology, and classification of gastroenteropancreatic NETs; clinical features of primary carcinoid tumors; diagnosis of carcinoid syndrome and tumor localization; the treatment of early-stage carcinoids; bronchial carcinoids; thymic carcinoids; management of symptoms of the carcinoid syndrome; and evaluation and management of neuroendocrine tumors of unknown primary site.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=high-grade-gastroenteropancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;High-grade gastroenteropancreatic neuroendocrine neoplasms&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring\" class=\"medical medical_review\">&quot;Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system\" class=\"medical medical_review\">&quot;Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-characteristics-of-well-differentiated-neuroendocrine-carcinoid-tumors-arising-in-the-tubular-digestive-tract-lung-and-genitourinary-tract\" class=\"medical medical_review\">&quot;Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the tubular digestive tract, lung, and genitourinary tract&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=diagnosis-of-the-carcinoid-syndrome-and-tumor-localization\" class=\"medical medical_review\">&quot;Diagnosis of the carcinoid syndrome and tumor localization&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=staging-treatment-and-posttreatment-surveillance-of-nonmetastatic-well-differentiated-gastrointestinal-tract-neuroendocrine-carcinoid-tumors\" class=\"medical medical_review\">&quot;Staging, treatment, and posttreatment surveillance of nonmetastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lung-neuroendocrine-carcinoid-tumors-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Lung neuroendocrine (carcinoid) tumors: Treatment and prognosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=thymic-neuroendocrine-carcinoid-tumors\" class=\"medical medical_review\">&quot;Thymic neuroendocrine (carcinoid) tumors&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-the-carcinoid-syndrome\" class=\"medical medical_review\">&quot;Treatment of the carcinoid syndrome&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=neuroendocrine-neoplasms-of-unknown-primary-site\" class=\"medical medical_review\">&quot;Neuroendocrine neoplasms of unknown primary site&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1973644\"><span class=\"h1\">CLASSIFICATION, BIOLOGIC BEHAVIOR, AND IMPLICATIONS FOR TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The World Health Organization (WHO) classifies all gastroenteropancreatic neuroendocrine tumors (NETs) into low-grade (G1), intermediate-grade (G2), and high-grade (G3) categories based upon mitotic count and proliferative index (Ki-67) (<a href=\"image.htm?imageKey=ONC%2F60365\" class=\"graphic graphic_table graphicRef60365 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/2\" class=\"abstract_t\">2</a>]. Poorly-differentiated neuroendocrine tumors are G3 neuroendocrine carcinomas. (See <a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system#H2474956\" class=\"medical medical_review\">&quot;Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system&quot;, section on '2010 WHO classification and 2017 update'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Well-differentiated NETs arising within the digestive system have been traditionally referred to as carcinoids when they arise within the tubular gastrointestinal tract and pancreatic NETs (islet cell tumors) when they arise in the pancreas or, in the case of gastrinoma, the proximal duodenum. Gastrointestinal and pancreatic NETs may have similar characteristics on routine histologic evaluation, but they have a different pathogenesis and biology [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/3\" class=\"abstract_t\">3</a>]. Pancreatic NETs have a worse prognosis than carcinoid tumors [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/4,5\" class=\"abstract_t\">4,5</a>] and respond differently to anticancer agents, with most agents demonstrating higher response rates among patients with pancreatic NETs than in those with carcinoids. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>G2 gastroenteropancreatic NETs have a slightly worse prognosis than G1 tumors [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Although they are treated similarly at present, as new treatment modalities become available, it is likely that the histologic grade of a well-differentiated NET will affect the selection of appropriate treatment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In contrast, poorly-differentiated neuroendocrine carcinomas have a rapidly progressive clinical course and a poor prognosis. They are generally treated with platinum-based chemotherapy regimens according to small cell lung carcinoma guidelines. (See <a href=\"topic.htm?path=high-grade-gastroenteropancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;High-grade gastroenteropancreatic neuroendocrine neoplasms&quot;</a> and <a href=\"topic.htm?path=extensive-stage-small-cell-lung-cancer-initial-management\" class=\"medical medical_review\">&quot;Extensive stage small cell lung cancer: Initial management&quot;</a>.)</p><p/><p>As a group, well-differentiated gastrointestinal NETs are generally indolent malignancies with a prolonged natural history. However, clinical behavior is heterogeneous. As an example, among patients with metastatic carcinoids, survival, according to the Surveillance, Epidemiology, and End Results (SEER) registry data, varies according to primary site; it is worst for patients with lung and colon primaries (median survival for distant grade 1 or 2 disease 24 and 14 months, respectively) and is most favorable for tumors arising in the small intestine (median survival 103 months) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/5\" class=\"abstract_t\">5</a>]. This heterogeneity in clinical behavior complicates the comparative assessment of benefit from individual therapies. (See <a href=\"topic.htm?path=staging-treatment-and-posttreatment-surveillance-of-nonmetastatic-well-differentiated-gastrointestinal-tract-neuroendocrine-carcinoid-tumors#H19140597\" class=\"medical medical_review\">&quot;Staging, treatment, and posttreatment surveillance of nonmetastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors&quot;, section on 'Stage and site of origin'</a>.)</p><p class=\"headingAnchor\" id=\"H1974073\"><span class=\"h1\">GENERAL APPROACH TO THE PATIENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of patients with advanced metastatic gastrointestinal neuroendocrine tumors (GINETs) have liver metastases [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/7\" class=\"abstract_t\">7</a>]. An approach to management is outlined in the algorithm (<a href=\"image.htm?imageKey=ONC%2F104426\" class=\"graphic graphic_algorithm graphicRef104426 \">algorithm 1</a>) and summarized below:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Potentially resectable disease </strong>&ndash; For patients who have potentially resectable disease, resection may provide prolonged control of symptoms and tumor growth. Although the majority of patients recur, even after a complete resection, metastasectomy is generally preferred over medical therapy for patients with potentially resectable liver metastases. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691406\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Surgical resection'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Unresectable, symptomatic disease</strong> &ndash; For patients with unresectable symptomatic disease, initial therapy with a somatostatin analog is highly effective for controlling symptoms of the carcinoid syndrome and for control of tumor growth. (See <a href=\"#H447989550\" class=\"local\">'Patients with symptoms from hormone hypersecretion'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Unresectable, asymptomatic disease </strong>&ndash; Initial therapy for asymptomatic patients with unresectable disease must be individualized. Therapeutic options in this situation include observation, particularly if tumor burden is limited, or initial therapy with a somatostatin analog, particularly if tumor burden is high (see <a href=\"#H190948935\" class=\"local\">'Control of tumor growth'</a> below). If an initial approach of observation is chosen, initiation of a somatostatin analog should be considered at time of progression.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Therapy for progression of hormone-related symptoms</strong> &ndash; Patients who have worsening symptoms of hormone secretion may benefit from escalation of somatostatin analog.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Therapy at progression </strong>&ndash; For patients with radiologic disease progression despite use of a somatostatin analog, therapeutic options for patients with hepatic predominant disease include systemic therapy, noncurative debulking surgery (in highly selected patients), or nonsurgical liver-directed therapy (eg, transarterial bland embolization, chemoembolization, or radioembolization). (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691398\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Hepatic predominant metastatic disease'</a> and <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691441\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Nonsurgical liver-directed therapy'</a>.)</p><p/><p class=\"bulletIndent1\">For patients with more widespread disease that is not eligible for liver-directed therapy, options include <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> (which was approved in the United States in February 2016 for the treatment of adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal origin with unresectable, locally advanced or metastatic disease) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/8\" class=\"abstract_t\">8</a>] and, for patients with somatostatin-receptor-positive tumors, peptide receptor radioligand therapy (eg, <a href=\"topic.htm?path=lutetium-lu-177-dotatate-drug-information\" class=\"drug drug_general\">lutetium Lu-177 dotatate</a> [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/9\" class=\"abstract_t\">9</a>]), where available. The value of cytotoxic chemotherapy continues to be debated, and no specific regimen can be recommended. (See <a href=\"#H168515036\" class=\"local\">'Molecularly targeted therapy'</a> below and <a href=\"#H86380552\" class=\"local\">'Peptide receptor radioligand therapy'</a> below and <a href=\"#H190948956\" class=\"local\">'Cytotoxic chemotherapy'</a> below.)</p><p/><p>The following sections will discuss the various systemic treatment options to control symptoms and tumor growth. Local treatment options are discussed in detail elsewhere. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H190948921\"><span class=\"h1\">SOMATOSTATIN ANALOGS</span></p><p class=\"headingAnchor\" id=\"H447989550\"><span class=\"h2\">Patients with symptoms from hormone hypersecretion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with symptomatic carcinoid syndrome from a gastrointestinal neuroendocrine tumor (GINET) and unresectable disease, we recommend initial treatment with a somatostatin analog. However, for patients with metastatic disease that is resectable with curative intent without extrahepatic metastases, diffuse bilobar involvement, or compromised liver function, resection is preferred over medical therapy.</p><p>Patients with metastases from a GINET often become symptomatic from hormone hypersecretion rather than from tumor bulk. This is especially true for patients with midgut (small bowel or appendiceal) carcinoids, in whom symptoms are typically absent until hepatic metastases supervene. In such cases, vasoactive substances, such as serotonin, enter the systemic circulation, causing the carcinoid syndrome. (See <a href=\"topic.htm?path=clinical-features-of-the-carcinoid-syndrome\" class=\"medical medical_review\">&quot;Clinical features of the carcinoid syndrome&quot;</a>.)</p><p>Somatostatin is a 14-amino acid peptide that inhibits the secretion of a broad range of hormones. It acts by binding to somatostatin receptor subtypes 2 and 5, which are expressed in high density in the majority of GINETs [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/10,11\" class=\"abstract_t\">10,11</a>]. The presence of somatostatin receptors can be determined using a radiolabeled form of the somatostatin analog <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (indium-111 [111-In] pentetreotide [OctreoScan]) or <a href=\"topic.htm?path=gallium-ga-68-dotatate-drug-information\" class=\"drug drug_general\">Gallium Ga-68 DOTATATE</a> (68-Ga DOTATATE) positron emission tomography <span class=\"nowrap\">(PET)/computed</span> tomography (CT). While traditional imaging with either 111-In pentetreotide or 68-Ga DOTATATE can be used to assess somatostatin receptor status in patients with neuroendocrine tumors (NETs), the higher sensitivity of 68-Ga DOTATATE suggests that this may the preferred option in certain clinical scenarios, particularly in patients with smaller tumor volume. However, a positive scan does not necessarily correlate with objective responses or duration of disease control [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/12\" class=\"abstract_t\">12</a>]. Furthermore, in some cases (eg, carcinoid syndrome, miliary disease spread), a therapeutic trial of a somatostatin analog could be considered, even in the presence of a negative scan. (See <a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring#H5\" class=\"medical medical_review\">&quot;Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring&quot;, section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p>Somatostatin analogs, including <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> and <a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">lanreotide</a>, are highly effective in controlling the symptoms associated with GINETs. The first study of a somatostatin analog in patients with carcinoid syndrome included 25 patients treated with octreotide 150 mcg subcutaneously three times daily [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/13\" class=\"abstract_t\">13</a>]. Control of flushing and diarrhea was achieved by 88 percent of patients, and a &ge;50 percent reduction of urinary 5-hydroxyindoleacetic acid (5-HIAA) levels was also noted in 72 percent of patients. Subsequent studies showed complete or partial relief of flushing <span class=\"nowrap\">and/or</span> diarrhea in 50 to 90 percent of patients [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/13-22\" class=\"abstract_t\">13-22</a>]. </p><p>Patients with the rare GINET-associated Cushing syndrome or acromegaly, associated with ectopic secretion of corticotropin (ACTH) or growth hormone releasing hormone (GHRH), respectively, may also experience symptomatic relief with somatostatin analogs [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/23,24\" class=\"abstract_t\">23,24</a>].</p><p>The use of somatostatin analogs for treatment of carcinoid syndrome and management of refractory symptoms is discussed in more detail elsewhere. (See <a href=\"topic.htm?path=treatment-of-the-carcinoid-syndrome#H624742796\" class=\"medical medical_review\">&quot;Treatment of the carcinoid syndrome&quot;, section on 'Somatostatin-analog therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H541868112\"><span class=\"h3\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptomatic patients may be initiated on short-acting <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> with rapid transition to a long-acting formulation and subsequent titration of dose to optimize symptom control. A depot preparation (octreotide LAR) has largely eliminated the need for daily octreotide injections and is now considered a standard approach for symptomatic treatment of advanced NETs [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/25,26\" class=\"abstract_t\">25,26</a>]. Octreotide LAR is typically initiated at a dose of 20 to 30 mg intramuscularly monthly with dose escalation as needed for optimal symptom control [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/27\" class=\"abstract_t\">27</a>]. Although dose escalation up to 60 mg monthly can be considered for symptom control, the efficacy of doses of octreotide LAR higher than 30 mg monthly has not been prospectively established [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/28\" class=\"abstract_t\">28</a>]. There is some evidence that somatostatin receptors may be saturated at an octreotide LAR dose of 60 mg; higher doses may be associated with minimal marginal symptomatic benefit [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/29\" class=\"abstract_t\">29</a>]. </p><p>Patients who experience symptom exacerbation toward the final week of each treatment cycle may benefit from an increased frequency of administration (ie, every three weeks). In other cases, patients may use additional short-acting <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> for breakthrough symptoms; therapeutic levels of octreotide are not reached until 10 to 14 days after the initiation of the LAR injection.</p><p><a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">Lanreotide</a>, another long-acting somatostatin analog that is approved both in Europe and the United States for treatment of unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic NETs and carcinoid syndrome, appears to have similar clinical efficacy to <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> in the treatment of metastatic NETs and the carcinoid syndrome [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/30-32\" class=\"abstract_t\">30-32</a>]. (See <a href=\"#H190948935\" class=\"local\">'Control of tumor growth'</a> below.)</p><p>Depot <a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">lanreotide</a> can be self-administered once monthly as a deep subcutaneous injection at doses ranging from 60 to 120 mg every four weeks.</p><p class=\"headingAnchor\" id=\"H541868118\"><span class=\"h3\">Side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Somatostatin analogs are usually well-tolerated, and side effects are generally mild [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/33,34\" class=\"abstract_t\">33,34</a>]. Approximately one-third of patients may have mild nausea, abdominal discomfort, bloating, loose stools, and fat malabsorption during the first weeks of therapy, after which time, symptoms tend to subside. Use of pancreatic enzyme supplements can ameliorate symptoms associated with pancreatic insufficiency [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/35\" class=\"abstract_t\">35</a>]. Mild glucose intolerance may occur due to transient inhibition of insulin secretion. Somatostatin analogs reduce postprandial gallbladder contractility and may delay gallbladder emptying; up to 25 percent of patients develop asymptomatic gallstones or sludge within the first 18 months of therapy [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"headingAnchor\" id=\"H447989628\"><span class=\"h3\">Prevention and management of carcinoid crisis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carcinoid crisis is a life-threatening form of carcinoid syndrome that may be triggered by tumor manipulation (biopsy, palpation at the bedside or during surgery) or by anesthesia. It is less commonly reported after chemotherapy, hepatic arterial embolization, or radionuclide therapy and occurs mostly in patients with extensive tumor bulk. Carcinoid crisis results from the release of an overwhelming amount of biologically active compounds from the tumor (<a href=\"image.htm?imageKey=ENDO%2F79329\" class=\"graphic graphic_table graphicRef79329 \">table 2</a>). In addition to hemodynamic instability, symptoms include flushing, diarrhea, tachycardia, arrhythmias, bronchospasm, and altered mental status. </p><p>Somatostatin analogs should be readily available during any surgical procedure. Preoperative administration of <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (300 mcg) can reduce the incidence of carcinoid crisis and is recommended for patients with a history of carcinoid syndrome who require surgical procedures. Intraoperatively, treatment for carcinoid crisis differs from that for other causes of acute hypotension. Symptoms are generally refractory to fluid resuscitation alone. Calcium and catecholamine vasopressors may provoke a release of mediators from the tumor and worsen, rather than ameliorate, the syndrome [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/36\" class=\"abstract_t\">36</a>]. During a carcinoid crisis, the blood pressure should be supported by infusion of plasma and octreotide (300 mcg IV) given immediately. A continuous IV drip of octreotide (50 to 100 <span class=\"nowrap\">mcg/hour)</span> may be needed. In patients with high risk of carcinoid crisis, an IV octreotide drip may be initiated preoperatively. The symptoms, prevention, and management of carcinoid crisis are discussed in more detail elsewhere. (See <a href=\"topic.htm?path=treatment-of-the-carcinoid-syndrome#H624742810\" class=\"medical medical_review\">&quot;Treatment of the carcinoid syndrome&quot;, section on 'Prevention and management of carcinoid crisis'</a>.)</p><p class=\"headingAnchor\" id=\"H1648278982\"><span class=\"h2\">Carcinoid heart disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with carcinoid heart disease, treatment with a somatostatin analog represents a main therapeutic modality. </p><p>Carcinoid heart disease, which is characterized by plaque-like fibrous thickening classically involving the valves of the right heart, can develop in up to one-half of patients with carcinoid syndrome. Indirect evidence supporting the role of serotonin in the pathogenesis of carcinoid heart disease comes from studies demonstrating higher serum serotonin levels and urinary 5-HIAA levels in patients with carcinoid heart disease compared with those without heart disease. (See <a href=\"topic.htm?path=carcinoid-heart-disease#H2\" class=\"medical medical_review\">&quot;Carcinoid heart disease&quot;, section on 'Pathophysiology'</a>.) </p><p>It appears that the incidence of carcinoid heart disease has decreased over the past several decades, possibly due to increased use of somatostatin analogs. It, however, remains uncertain whether somatostatin analog therapy can inhibit or reverse progression of existing carcinoid heart disease. (See <a href=\"topic.htm?path=carcinoid-heart-disease#H277922450\" class=\"medical medical_review\">&quot;Carcinoid heart disease&quot;, section on 'Treatment of carcinoid syndrome'</a>.)</p><p>Consistent with guidelines from the <a href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&amp;token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL/3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo=&amp;TOPIC_ID=16901\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network (NCCN)</a>, we recommend an echocardiogram to evaluate for the presence of carcinoid heart disease in patients with a murmur or signs or symptoms of heart disease, or in whom major surgery is planned. Other guidelines advocate routine echocardiogram in all patients with carcinoid syndrome [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/37\" class=\"abstract_t\">37</a>]. (See <a href=\"topic.htm?path=carcinoid-heart-disease#H9\" class=\"medical medical_review\">&quot;Carcinoid heart disease&quot;, section on 'Echocardiography'</a>.)</p><p class=\"headingAnchor\" id=\"H190948935\"><span class=\"h2\">Control of tumor growth</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to controlling symptoms associated with hormone hypersecretion, somatostatin analogs have also been shown to control tumor growth. Given the variable and sometimes indolent disease course of some GINETs, the optimal time to initiate treatment with a somatostatin analog in asymptomatic patients remains uncertain. We suggest initiation of a somatostatin analog in patients with unresectable, asymptomatic, somatostatin-receptor positive, well-differentiated GINETs and a high tumor burden, an approach that is consistent with guidelines from the European Neuroendocrine Tumor Society (ENETS) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/26\" class=\"abstract_t\">26</a>], the North American Neuroendocrine Society (NANETS) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/38\" class=\"abstract_t\">38</a>], and the <a href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&amp;token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL/3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo=&amp;TOPIC_ID=16901\" target=\"_blank\" class=\"external\">NCCN</a>. For patients with asymptomatic, advanced, unresectable GINETs and small volume disease, we suggest observation alone rather than early administration of a somatostatin analog. In such patients, we initiate somatostatin analog therapy if there is evidence of clinically meaningful tumor progression. </p><p>Past studies indicated that &lt;10 percent of patients with advanced GINETs have objective tumor shrinkage with somatostatin analogs, although prolonged periods of stable disease are seen in up to 66 percent of cases [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/13,14,39-48\" class=\"abstract_t\">13,14,39-48</a>]. However, more recent reports suggest that, in addition to an improvement in symptoms, treatment with somatostatin analogs can significantly delay progression [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/41,49,50\" class=\"abstract_t\">41,49,50</a>]. Whether somatostatin analogs also increase overall survival is not yet known, although a correlation between progression-free survival (PFS) and overall survival in patients with advanced NET treated with single-agent somatostatin analog therapy has been shown [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/51\" class=\"abstract_t\">51</a>]. </p><p>In the PROMID trial, 85 patients with locally inoperable or metastatic small bowel gastrointestinal NETs were randomly assigned to receive treatment with either long-acting <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (Sandostatin LAR 30 mg monthly) or placebo [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/41\" class=\"abstract_t\">41</a>]. The median time to tumor progression was significantly longer with octreotide compared with placebo (14.3 versus 6 months), confirming an antitumor effect in this population. Patients with functionally active and inactive tumors appeared to have a similar benefit. In a later report, while a trend toward improved overall survival was observed in the patients randomized to receive octreotide, the number of patients in this study was relatively small, and the difference was not statistically significant [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/52\" class=\"abstract_t\">52</a>].</p><p>Further support for the antiproliferative effect of somatostatin analogs in patients with gastroenteropancreatic NETs was provided by the CLARINET trial, a randomized, placebo-controlled, phase III trial evaluating the antiproliferative effects of <a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">lanreotide</a> in 204 patients with advanced well- or moderately-differentiated, non-functioning, gastroenteropancreatic NETs, including both GINETs and pancreatic NETs [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/49\" class=\"abstract_t\">49</a>]. Patients were randomly assigned to either 120 mg lanreotide Autogel (n = 101) or placebo (n = 103) every four weeks for 96 weeks or until progressive disease or death. The primary endpoint for the trial was PFS as determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (<a href=\"image.htm?imageKey=ONC%2F74693\" class=\"graphic graphic_table graphicRef74693 \">table 3</a>). Most patients (96 percent) had no tumor progression in the three to six months before randomization. Compared with placebo, there was a highly significant advantage in PFS with the use of lanreotide. At a time-point of two years following initiation of treatment, median PFS was not reached with lanreotide, compared with 18 months with placebo (hazard ratio [HR] for progression or death 0.47; 95% CI 0.30-0.73). Estimated rates of PFS at 24 months were 65 versus 33 percent, and there were no differences in quality of life or overall survival. The most common treatment related adverse effect was diarrhea (26 versus 9 percent with lanreotide and placebo, respectively). Based upon these data, lanreotide has been approved in the United States for the treatment of patients with unresectable, well- or moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic NETs.</p><p>As with symptomatic patients, we typically initiate therapy with 20 or 30 mg of long-acting <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> monthly. Whether higher or escalating doses of a somatostatin analog provide higher rates of disease control is unclear. Three retrospective studies using either octreotide LAR (160 mg intramuscularly every 14 days for two months, then monthly) or <a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">lanreotide</a> (750 to 15,000 mcg per day) demonstrated disease stabilization in 37 to 75 percent of patients [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/19,53,54\" class=\"abstract_t\">19,53,54</a>]. However, the number of patients included in these studies was small (12 to 30), follow-up was short (&le;12 months), and the number of objective responses was not higher than reported with conventional doses (3 to 5 percent). </p><p class=\"headingAnchor\" id=\"H190948949\"><span class=\"h1\">INTERFERON</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The role of interferon alfa (IFNa) in the modern treatment of advanced gastrointestinal neuroendocrine tumor (GINET) is uncertain. While IFNa is an option for patients with advanced GINETs who have worsening symptoms while on treatment with somatostatin analogs or who are intolerant of somatostatin analog therapy, widespread acceptance of this agent for the treatment of advanced GINETs has been limited by the potential for severe side effects. Guidelines from the European Neuroendocrine Tumor Society (ENETS) and the North American Neuroendocrine Tumor Society (NANETS), which preceded information on the effectiveness of <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> and peptide receptor radioligand therapy, include IFNa as a second-line therapy for functioning GINETs after failure of a somatostatin analog [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/26,38\" class=\"abstract_t\">26,38</a>], while <a href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&amp;token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL/3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo=&amp;TOPIC_ID=16901\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network (NCCN)</a> guidelines endorse the use of IFNa for patients with progressive metastases for whom there are no other treatment options. (See <a href=\"#H168515048\" class=\"local\">'Everolimus'</a> below and <a href=\"#H86380552\" class=\"local\">'Peptide receptor radioligand therapy'</a> below.)</p><p>IFNa has been used as a treatment for advanced carcinoid for several decades. Interferon (IFN) receptors are expressed in neuroendocrine neoplasms [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/55\" class=\"abstract_t\">55</a>]. Interferons can exert antitumor effects via stimulation of T cells, induction of cell cycle arrest, <span class=\"nowrap\">and/or</span> inhibition of angiogenesis [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/56,57\" class=\"abstract_t\">56,57</a>]. The ability of IFNa to control the secretion of tumor products led to its initial use in patients with the carcinoid syndrome [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/58\" class=\"abstract_t\">58</a>]. </p><p>In large, retrospective series, low-dose IFNa reduces symptoms of hormonal hypersecretion in 40 to 70 percent of patients with gastrointestinal neuroendocrine tumors (NETs) and induces tumor stabilization in 20 to 40 percent [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/14,45,59-70\" class=\"abstract_t\">14,45,59-70</a>]. As with somatostatin analogs, tumor regression is less common, although it is reported in up to 20 percent of patients in some studies [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/14,58,60,62-65,69\" class=\"abstract_t\">14,58,60,62-65,69</a>].</p><p>IFNa doses have ranged from 3 to 9 million units (MU) and have been administered subcutaneously from three to seven times per week. The usual dose is 3 to 5 MU three times weekly [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/71\" class=\"abstract_t\">71</a>]. IFNa is somewhat myelosuppressive, and the dose is often titrated in individual patients to achieve a total leukocyte count of <span class=\"nowrap\">3000/microL</span>. </p><p>Use of IFNa is limited by severe side effects, including fatigue, depression, myelosuppression, flu-like symptoms, weight loss, and alteration of thyroid function [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/72\" class=\"abstract_t\">72</a>]. For better tolerability, pegylated IFN (80 to 150 mcg per week, subcutaneously) may be considered for symptomatic patients who are refractory to somatostatin analogs and other forms of therapy (eg, <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>) and who do not tolerate conventional IFNa, although the data in patients with neuroendocrine tumors are quite limited [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/73,74\" class=\"abstract_t\">73,74</a>], and pegylated IFN is not approved for this indication.</p><p class=\"headingAnchor\" id=\"H447989844\"><span class=\"h2\">IFNa plus a somatostatin analog</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest initiating therapy for symptomatic patients with a somatostatin analog alone rather than a combination of a somatostatin analog and IFNa; this approach is consistent with guidelines from the NANETS [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/38\" class=\"abstract_t\">38</a>], ENETS [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/26\" class=\"abstract_t\">26</a>], and the <a href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&amp;token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL/3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo=&amp;TOPIC_ID=16901\" target=\"_blank\" class=\"external\">NCCN</a>. </p><p>Relatively few prospective studies have evaluated IFN in combination with somatostatin analogs compared with somatostatin analogs alone, and the results are conflicting:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective trial of 68 patients with liver metastases who were randomly assigned to initial therapy with <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (100 mcg twice daily, increased to 200 mcg three times daily for persistent carcinoid symptoms) alone or with IFNa, both treatments were equally effective at reducing urinary 5-hydroxyindoleacetic acid (5-HIAA) levels [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/75\" class=\"abstract_t\">75</a>]. However, patients receiving combined therapy had a significantly reduced risk of tumor progression when compared with patients receiving octreotide alone, suggesting that the addition of IFN had a significant antitumor effect. (See <a href=\"topic.htm?path=diagnosis-of-the-carcinoid-syndrome-and-tumor-localization#H3\" class=\"medical medical_review\">&quot;Diagnosis of the carcinoid syndrome and tumor localization&quot;, section on 'Urinary excretion of 5-HIAA'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On the other hand, two other randomized trials have not demonstrated improvements in tumor response or time to radiologic disease progression with combined therapy as a first-line treatment for progressive gastrointestinal NETs:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The comparable efficacy of <a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">lanreotide</a>, IFNa, or combined therapy was evaluated in a prospective randomized trial involving 80 therapy-naive patients with documented progressive metastatic gastrointestinal NETs [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/45\" class=\"abstract_t\">45</a>]. Objective partial response rates were comparably low in all three groups (4, 4, and 7 percent for lanreotide, IFN, and combined therapy, respectively), and the number of patients who achieved disease stabilization was not substantially higher with combined therapy (28, 26, and 18 percent for lanreotide, IFN, and the combination, respectively).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Similar findings were noted in a second trial, in which 109 patients with progressive metastatic gastrointestinal NETs were randomly assigned to <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> with or without IFNa [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/76\" class=\"abstract_t\">76</a>]. At 3, 6, and 12 months, rates of objective partial response were low (3, 2, and 6 percent, respectively) and similar with octreotide alone or plus IFNa. There were also no significant differences between the two groups in the rates of stable disease at the three time points, time to treatment failure, or long-term survival. </p><p/><p>These studies, however, were likely underpowered to detect significant differences between the arms. The combination of <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> plus either IFNa or <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> was evaluated in a large randomized study performed by the Southwest Oncology Group (SWOG) and the North American Intergroup (SWOG S0518), and is discussed below. (See <a href=\"#H168515075\" class=\"local\">'Bevacizumab'</a> below.) &#160;</p><p class=\"headingAnchor\" id=\"H168515036\"><span class=\"h1\">MOLECULARLY TARGETED THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Molecularly targeted therapy for neuroendocrine tumors (NETs), including gastrointestinal NETs (GINETs), includes agents that target the vascular endothelial growth factor (VEGF) and <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>, an inhibitor of the mammalian target of rapamycin (mTOR).</p><p>NETs are among the most highly vascular of solid tumors and frequently express the VEGF and its receptor (VEGFR), which are key drivers of angiogenesis. In preclinical models, disruption of these and other signaling pathways inhibits neuroendocrine cell growth. VEGF-targeting agents can be generally divided into two categories: antiangiogenic small molecular tyrosine kinase (TK) inhibitors and circulating VEGF inhibitors, of which the most commonly used is the anti-VEGF monoclonal antibody <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>.</p><p>The mTOR is a threonine kinase that mediates downstream signaling in a number of pathways that are implicated in NET growth, including the VEGF and insulin-like growth factor (IGF) signaling pathways [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/11,77\" class=\"abstract_t\">11,77</a>]. In addition, mTOR regulates angiogenesis by controlling the production of hypoxia inducible factor.</p><p>Among patients with gastroenteropancreatic NETs, studies have demonstrated antitumor activity associated with <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> and several TK inhibitors that inhibit VEGFR (including <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a>), as well as the mTOR inhibitor <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>. A progression-free survival (PFS) benefit has been shown for everolimus and sunitinib as single agents in patients with pancreatic NETs, leading to the approval of both compounds in the United States for treatment of advanced pancreatic NETs. However, in contrast to pancreatic NETs, the benefit of molecularly-targeted therapy for GINETs is less well-established. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90694077\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Molecularly targeted therapy'</a>.) </p><p class=\"headingAnchor\" id=\"H168515048\"><span class=\"h2\">Everolimus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with a GINET and progressive disease despite a somatostatin analog who are not eligible for liver-directed therapy, we suggest <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>.</p><p>The benefit of <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> for GINET has been evaluated in the following studies (<a href=\"image.htm?imageKey=ONC%2F90847\" class=\"graphic graphic_table graphicRef90847 \">table 4</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a phase II study of <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> in conjunction with <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> in 30 patients with advanced GINETs, partial responses were observed in 5 of 30 (17 percent) patients, but the median time to tumor progression was relatively short, under eight months [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/78\" class=\"abstract_t\">78</a>].</p><p/><p class=\"bulletIndent1\">Further support for associated antitumor activity comes from a phase II trial, in which 34 patients with radiologically progressing, locally advanced, recurrent, or metastatic but nonfunctioning NETs at a variety of sites, including the intestinal tract (n = 22), received <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> 10 mg daily [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/79\" class=\"abstract_t\">79</a>]. The best response was a partial response in three patients and stable disease in 28, for an overall disease control rate of 94 percent. The median PFS was 15.3 months, and the four-month PFS rate was 78 percent. The major grade 3 or 4 adverse events were thrombocytopenia (15 percent), hyperglycemia, stomatitis, and anemia (6 percent each).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two phase III trials have been conducted, both of which suggest benefit compared with long-acting <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> alone or placebo:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The RADIANT 2 trial randomly assigned 429 patients with advanced GINETs, a history of carcinoid syndrome, and radiologic disease progression in the preceding 12 months to <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> LAR (30 mg intramuscularly every 28 days) with or without <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> (10 mg daily) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/80,81\" class=\"abstract_t\">80,81</a>]. As assessed by central radiographic review, combined therapy was associated with a potentially clinically meaningful prolongation in median PFS, but it was only of borderline statistical significance (16.4 versus 11.3 months; hazard ratio [HR] for tumor progression 0.77, 95% CI 0.59-1.0). Imbalances between study groups were noted in important prognostic variables, including disease site and performance status, all of which favored the control group and could have affected the primary outcome results. A later analysis, presented at the 2012 American Society of Clinical Oncology (ASCO) gastrointestinal (GI) Cancers Symposium, found a significant PFS benefit for everolimus after adjusting for randomization imbalances (HR for progression 0.62, 95% CI 0.51-0.87, p = 0.003) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/81\" class=\"abstract_t\">81</a>].</p><p/><p class=\"bulletIndent2\">In the final analysis, there was no significant difference in overall survival between the two groups (HR for death 1.17, 95% CI 0.92-1.49) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/82\" class=\"abstract_t\">82</a>]; however, patients who were randomly assigned to the placebo group were permitted to cross over to the active treatment group, potentially obscuring any meaningful survival benefit.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The most definitive demonstration of benefit from <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> comes from the <a href=\"http://clinicaltrials.gov/ct2/show/NCT01524783?term=(NCT01524783).&rank=1&amp;token=YbJELcAW9G3aZfZrjTwgljvGy8B5W5sYbMw5bZWXTZnIhXVOYkOVnoCwwUV3IFyHglWLtnztWHFwnBGz19y/OLF8i6Tz7GT/YcYlQqcbx7E=&amp;TOPIC_ID=16901\" target=\"_blank\" class=\"external\">RADIANT-4 trial</a>, a phase III study in which 302 patients with advanced, nonfunctional lung or GINETs (most common sites: lung [30 percent], ileum [24 percent], and rectum [13 percent]) were randomly assigned to everolimus or placebo [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/8\" class=\"abstract_t\">8</a>]. Everolimus was associated with a significant improvement in median PFS, the primary endpoint (11 versus 3.9 months; HR for progression 0.48, 95% CI 0.35-0.67). There was an overall objective response rate of 2 percent for everolimus compared with 1 percent for placebo, but the disease control rate was 81 percent for patients assigned to everolimus compared with 64 percent for placebo. Adverse events were mainly grade 1 or 2 and included stomatitis, diarrhea, peripheral edema, fatigue, and rash. Most frequent severe (grade 3 or 4) adverse events, which were more common with everolimus, were diarrhea (7 versus 2 percent), stomatitis (9 versus 0 percent), and anemia (5 versus 2 percent). In the most recent update presented at the 2016 annual ASCO meeting, at a median follow-up of 33 months, everolimus was associated with a 27 percent reduction in the risk of death, but the difference was not statistically significant (HR 0.73; 95% CI 0.48-1.11; two-year survival 77 versus 62 percent) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/83\" class=\"abstract_t\">83</a>]. The benefits of everolimus were achieved while preserving overall quality of life [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/84\" class=\"abstract_t\">84</a>].</p><p/><p class=\"bulletIndent2\">Largely based upon these results, <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> was approved in February 2016 by the US Food and Drug Administration for the treatment of adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) tract origin with unresectable, locally advanced or metastatic disease.</p><p/><p class=\"headingAnchor\" id=\"H447989880\"><span class=\"h2\">Small molecule TK inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">Sunitinib</a>, <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>, <a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a>, and <a href=\"topic.htm?path=cabozantinib-drug-information\" class=\"drug drug_general\">cabozantinib</a> have been evaluated in advanced GINETs in phase II trials (<a href=\"image.htm?imageKey=ONC%2F90847\" class=\"graphic graphic_table graphicRef90847 \">table 4</a>). Response rates have been low, although all studies report a high rate of disease stabilization and potentially encouraging PFS durations. In the absence of randomized studies, the activity of these TK inhibitors in advanced GINETs remains uncertain, and their routine use is not currently recommended. </p><p>An ongoing <a href=\"https://clinicaltrials.gov/ct2/show/NCT01841736?term=01841736&rank=1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH+MCpwZ1/1ekxPM4QCnYsX3eQfDyJsBmFL1qA1Mb4hHjwalaMMGpaGzwZAduVhHbqSNgwpUEAbTZO2Q=&amp;TOPIC_ID=16901\" target=\"_blank\" class=\"external\">randomized phase II study being conducted by the Alliance for Clinical Trials in Oncology Group</a> (A021202) is evaluating the efficacy of <a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a> compared with placebo for patients with advanced carcinoid tumors. </p><p class=\"headingAnchor\" id=\"H168515075\"><span class=\"h2\">Bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Activity for <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> was suggested in a phase II trial, in which 44 patients with advanced or metastatic GINETs on a stable dose of <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> were randomly assigned to 18 weeks of bevacizumab or pegylated IFNa-2b (<a href=\"image.htm?imageKey=ONC%2F90847\" class=\"graphic graphic_table graphicRef90847 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/73\" class=\"abstract_t\">73</a>]. At disease progression or at the completion of 18 weeks of therapy (whichever came first), all patients received bevacizumab plus interferon. During the first 18 weeks of therapy, four (18 percent) of the bevacizumab-treated patients experienced radiographic partial responses, while 17 (77 percent) had stable disease. Furthermore, after 18 weeks, 95 percent of patients treated with octreotide plus bevacizumab remained progression-free compared with only 68 percent of those receiving octreotide plus IFNa-2b. </p><p>These results led to a large randomized <a href=\"http://clinicaltrials.gov/ct2/show/NCT00569127?term=NCT00569127&rank=1&amp;token=YbJELcAW9G3aZfZrjTwgljvGy8B5W5sYbMw5bZWXTZn9RbmLWJkc2ZsTnGzcXPKcn9rKJT+zUVdnh/LK1d7ULW7b0AgFM6ijyZ8cwmgcwQA=&amp;TOPIC_ID=16901\" target=\"_blank\" class=\"external\">study of octreotide plus bevacizumab versus octreotide plus interferon</a> in 427 patients with advanced (unresectable or metastatic) NETs of the gastrointestinal tract and lung with progressive disease or other indicators of poor prognosis (<a href=\"image.htm?imageKey=ONC%2F90847\" class=\"graphic graphic_table graphicRef90847 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/85\" class=\"abstract_t\">85</a>]. Radiologic responses were more frequent among patients treated with <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> (12 versus 4 percent), but median PFS (the primary endpoint as determined by central review) was not significantly different (16.6 versus 15.4 months). </p><p>A role for <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> in combination with <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> in the treatment of GINETs is not yet established. Results with bevacizumab in combination with <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> are discussed below. (See <a href=\"#H26472645\" class=\"local\">'Capecitabine plus bevacizumab'</a> below.)</p><p class=\"headingAnchor\" id=\"H86380552\"><span class=\"h1\">PEPTIDE RECEPTOR RADIOLIGAND THERAPY</span></p><p class=\"headingAnchor\" id=\"H86380627\"><span class=\"h2\">Radiolabeled somatostatin analogs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with somatostatin-receptor-positive gastrointestinal neuroendocrine tumors (GINETs) that are progressive despite standard-dose long-acting somatostatin analog therapy or despite somatostatin analog therapy and <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>, peptide receptor radioligand therapy (PRRT) using a radiolabeled somatostatin analog is a reasonable option, either at the time of progression on the somatostatin analog or following progression on everolimus. There are no data specifically comparing PRRT with everolimus in patients progressing on long-acting somatostatin analog therapy, and the choice of therapy in this situation should be based upon the availability of <a href=\"topic.htm?path=lutetium-lu-177-dotatate-drug-information\" class=\"drug drug_general\">lutetium Lu-177 dotatate</a> (<sup>177</sup>Lu-Dotatate) and patient preference. Somatostatin receptor expression is determined by use of diagnostic imaging using radiolabeled somatostatin analogs. (See <a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring#H5\" class=\"medical medical_review\">&quot;Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring&quot;, section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p>There has been substantial interest in targeted radiotherapy using radiolabeled somatostatin analogs [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/86-96\" class=\"abstract_t\">86-96</a>]. The most frequently used radionuclides for targeted radiotherapy include yttrium-90 (<sup>90</sup>Y) and lutetium-177 (<sup>177</sup>Lu), which differ from one another in terms of emitted particles, particle energy, and tissue penetration [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/97,98\" class=\"abstract_t\">97,98</a>]. In general, objective tumor response rates are up to 30 percent, and approximately one-third have symptomatic improvement. Long-term side effects include loss of renal function, pancytopenia, and myelodysplastic syndrome (MDS). (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90694162\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Radiolabeled somatostatin analogs'</a>.)</p><p>Most of the series reporting efficacy and toxicity with radiolabeled somatostatin analogs have included both pancreatic neuroendocrine tumors (NETs) and carcinoid tumors [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/92,99-101\" class=\"abstract_t\">92,99-101</a>].</p><p class=\"headingAnchor\" id=\"H545183865\"><span class=\"h3\">Yttrium-90 dotatoc</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most extensive experience with <sup>90</sup>Y-DOTA-TOC (<sup>90</sup>Y-Dotatoc) comes from a large single-institution series of 1109 patients with metastatic gastroenteropancreatic NETs and disease progression within 12 months of study entry, with visible tumor uptake on pretreatment somatostatin receptor scintigraphy [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/101\" class=\"abstract_t\">101</a>]. After the initial dose, additional treatment cycles were withheld if there was tumor progression or permanent toxicity; otherwise, patients were offered retreatment; the specific interval was not specified. The median number of courses administered was two, range 1 to 10.</p><p class=\"bulletIndent1\">Overall, 378 patients (34 percent) had a &quot;morphologic&quot; response (defined as any measurable decrease in the sum of the longest diameters of all pre-therapeutically detected tumor lesions by computed tomography [CT], magnetic resonance imaging [MRI], or ultrasound), 172 (15 percent) had a biochemical response (defined as any posttreatment decrease in a tumor marker that had demonstrated progression prior to enrollment), and 329 (29.7 percent) improved symptomatically. The median survival from diagnosis was 94.6 months. Longer survival correlated with responses by any of the above criteria. Transient grade 3 or 4 hematologic toxicities developed in 142 (12 percent), and loss of renal function was the main dose-limiting toxicity. In all, 103 patients (9 percent) had permanent grade 4 or 5 (fatal, n = 35) renal toxicity. Older age, low baseline glomerular filtration rate, and high kidney uptake score were associated with severe nephrotoxicity.</p><p/><p class=\"headingAnchor\" id=\"H1264345288\"><span class=\"h3\">Lutetium Lu-177 dotatate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increasing data suggest that <sup>177</sup>Lu-Dotatate outperforms <sup>90</sup>Y-Dotatoc, although randomized trials have not been undertaken [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/9,92,102\" class=\"abstract_t\">9,92,102</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most compelling demonstration of benefit for <sup>177</sup>Lu-Dotatate in midgut GINETs was shown in the phase III international NETTER-1 trial, in which 230 patients with inoperable, somatostatin-receptor-positive midgut NETs who experienced progressive disease on standard doses (20 to 30 mg every three to four weeks) of <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> LAR were randomly assigned to four doses of <sup>177</sup>Lu-Dotatate every eight weeks or octreotide LAR 60 mg every 28 days [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/9\" class=\"abstract_t\">9</a>]. The estimated rate of progression-free survival at month 20 was significantly higher with <sup>177</sup>Lu-Dotatate (65.2 versus 10.8 percent); median progression-free survival for octreotide LAR alone was 8.4 months, while it had not been reached in the <sup>177</sup>Lu-Dotatate group (with approximately 30 months of follow-up since initiation of treatment). An interim analysis also suggested longer overall survival with <sup>177</sup>Lu-Dotatate (14 versus 26 deaths, hazard ratio for death 0.40, p = 0.0004). The hazard ratio for disease progression or death favored <sup>177</sup>Lu-Dotatate (hazard ratio 0.21, 95% CI 0.13-0.33). Among patients evaluable for radiographic response, <sup>177</sup>Lu-Dotatate was also associated with a significantly higher objective response rate (18 versus 3 percent). Radiopharmaceutical therapy was well tolerated overall; serious adverse events that were considered related to treatment were more common with <sup>177</sup>Lu-Dotatate (9 versus 1 percent). The most common adverse event in the <sup>177</sup>Lu-Dotatate group was nausea (all grade, 59 percent; grade 3 or 4, four percent), thought to be due to the amino acid infusions administered during therapy to protect the kidneys. Hematologic toxicities included mostly mild degrees of thrombocytopenia (25 percent), lymphopenia (18 percent, grade 3 or 4 in 9 percent), anemia (14 percent), and leukopenia (10 percent). Long-term safety data, however, have not yet been reported for this trial.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Long-term safety data are available from a multicenter Dutch series of over 1200 patients treated with <sup>177</sup>Lu-Dotatate for advanced gastroenteropancreatic or lung NET [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/103\" class=\"abstract_t\">103</a>]. The median follow-up was 78 months. The safety analysis included 610 patients who had received a cumulative dose of at least 100 millicuries (3.7 gigabecquerels [GBq]). Long-term toxicity included acute leukemia in four patients (0.7 percent, three fatal) and MDS in nine (1.5 percent, five fatal). There was no therapy-related long-term renal or hepatic failure.</p><p/><p class=\"bulletIndent1\">The incidence and course of persistent hematologic dysfunction were addressed in another Dutch multicenter report that systematically followed 274 patients with gastroenteropancreatic NETs for at least five years following treatment with <sup>177</sup>Lu-Dotatate; the intended cumulative dose was 29.6 GBq (800 millicuries) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/104\" class=\"abstract_t\">104</a>]. Eleven patients (3.7 percent) had persistent hematological dysfunction posttreatment; these included eight with a hematologic neoplasm (four MDS, one acute myeloid leukemia [AML], one myeloproliferative neoplasm [MPN], and two <span class=\"nowrap\">MDS/MPN)</span> and three with bone marrow failure characterized by cytopenias and bone marrow aplasia. The median latency period was 41 months after the first PRRT cycle. No risk factors for persistent hematologic dysfunction could be identified.</p><p/><p class=\"bulletIndent1\">Rates of nephrotoxicity were low during therapy (1 percent) in another Dutch report of 209 patients treated with <sup>177</sup>Lu-Dotatate [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/105\" class=\"abstract_t\">105</a>]. Following treatment, the average annual decrease in creatinine clearance was 3.4 percent, and no patient had an annual decrease in renal function of &gt;20 percent. No risk factors for renal toxicity could be identified.</p><p/><p>Largely based upon data from the NETTER-1 trial, in January 2018, the US Food and Drug Administration (FDA) approved <sup>177</sup>Lu-Dotatate for the treatment of somatostatin-receptor-positive gastroenteropancreatic NETs in adults [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/106\" class=\"abstract_t\">106</a>]. The recommended dose is 7.4 GBq (200 millicuries) as an intravenous infusion over 30 minutes every eight weeks for a total of four doses [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/107\" class=\"abstract_t\">107</a>]. The limitations of <sup>177</sup>Lu-Dotatate at present include the complexity of administration, the lack of trials comparing this agent with other systemic therapies, such as <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>, and the lack of widespread availability. Potential late toxicities include late development of renal dysfunction and persistent hematologic dysfunction, including the development of treatment-related hematologic malignancies, although rare.</p><p>The optimal selection of candidates for <sup>177</sup>Lu-Dotatate is not established. Guidelines from the European Neuroendocrine Tumor Society (ENETS), which largely mirror the eligibility criteria for the NETTER-1 trial, are outlined in the table (<a href=\"image.htm?imageKey=ONC%2F116972\" class=\"graphic graphic_table graphicRef116972 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/108\" class=\"abstract_t\">108</a>]. We agree with these guidelines.</p><p class=\"headingAnchor\" id=\"H86381166\"><span class=\"h2\">MIBG</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Benefit also has been suggested for systemic radionuclide therapy using iodine-131-labeled metaiodobenzylguanidine (<sup>131</sup>I-MIBG) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/109,110\" class=\"abstract_t\">109,110</a>] in patients with metastatic gastroenteropancreatic NETs who have evidence of MIBG uptake as determined by <sup>123</sup>I-MIBG scanning. While <sup>131</sup>I-MIBG has been licensed by regulatory authorities in some countries [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/111\" class=\"abstract_t\">111</a>], in our view, its use for the treatment of GINETs remains investigational.</p><p>MIBG is a compound resembling norepinephrine that is accumulated by some neuroendocrine tumors. In two separate retrospective series, biochemical (5-HIAA) responses were observed in 37 percent of patients with gastroenteropancreatic NETs treated with <sup>131</sup>I-MIBG, and objective radiographic responses were noted in 15 and 28 percent, respectively [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/110,112\" class=\"abstract_t\">110,112</a>]. In one report, symptomatic improvement was reported by 27 of 48 patients (56 percent) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/112\" class=\"abstract_t\">112</a>].</p><p>However, the benefit of <sup>131</sup>I-MIBG was subsequently called into question in a nonrandomized comparison of outcomes with radiolabeled <sup>131</sup>I-MIBG in 30 patients with carcinoid syndrome or tumor symptoms (fever, pain) attributed to the carcinoid tumor versus unlabeled MIBG in 20 patients with carcinoid syndrome who were not suitable for treatment with the radioactive compound [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/113\" class=\"abstract_t\">113</a>]. The rate of symptom response was identical in both groups (60 percent), though symptom response was not accompanied by either a biochemical or radiographic response in any patient.</p><p class=\"headingAnchor\" id=\"H190948956\"><span class=\"h1\">CYTOTOXIC CHEMOTHERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The benefit of cytotoxic chemotherapy for advanced gastrointestinal neuroendocrine tumors (GINETs) continues to be debated. In general, we do not consider that any cytotoxic chemotherapy regimen represents a standard approach for treatment of advanced GINETs. This position is consistent with published guidelines from the European Neuroendocrine Tumor Society (ENETS) and North American Neuroendocrine Society (NANETS) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/26,38\" class=\"abstract_t\">26,38</a>]. Consensus-based guidelines from the <a href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&amp;token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL/3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo=&amp;TOPIC_ID=16901\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network (NCCN)</a> suggest that anticancer agents, such as <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a>, <a href=\"topic.htm?path=dacarbazine-drug-information\" class=\"drug drug_general\">dacarbazine</a>, <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a> (FU), and <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">temozolomide</a>, can be considered in patients with progressive metastases from a GINET for whom there are no other treatment options, although they emphasize the rarity of objective radiologic responses and the lack of a demonstration of a progression-free survival (PFS) or overall survival benefit in robust clinical trials. Regimens that have demonstrated evidence of activity in preliminary reports of phase II studies include <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a> plus short-term infusional FU plus <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (FOLFOX), and temozolomide plus capecitabine; however, in our view, confirmatory studies are needed to better define the activity of these regimens and to assess whether response may differ depending on primary site. </p><p>Among patients with well-differentiated GINETs, single-agent therapy with fluoropyrimidines, <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a>, <a href=\"topic.htm?path=dacarbazine-drug-information\" class=\"drug drug_general\">dacarbazine</a>, and <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> is associated with only modest response rates [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/114-116\" class=\"abstract_t\">114-116</a>]. As an example, single agent <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> (1000 <span class=\"nowrap\">mg/m<sup>2</sup></span> twice daily for 14 days every three weeks) was studied in a small phase II trial of 19 patients with metastatic neuroendocrine tumors (NETs; 12 arising in the gut, one in ovary, and six unknown) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/115\" class=\"abstract_t\">115</a>]. Although there were no radiologic partial or complete responses, 13 (68 percent) achieved stable disease radiographically, which lasted &gt;12 months in four patients; there were two patients with a &gt;50 percent decrease in the tumor marker chromogranin A (CGA) from baseline. Median PFS was 9.9 months, but median overall survival was 36.5 months. Other chemotherapeutic agents, such as the taxanes, <a href=\"topic.htm?path=topotecan-drug-information\" class=\"drug drug_general\">topotecan</a>, and <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>, are relatively inactive as single agents [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/117-120\" class=\"abstract_t\">117-120</a>].</p><p>Most studies in advanced GINETs have focused on streptozocin-based regimens (<a href=\"image.htm?imageKey=ONC%2F52299\" class=\"graphic graphic_table graphicRef52299 \">table 6</a>). </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An early Eastern Cooperative Oncology Group (ECOG) trial randomly assigned 118 patients to <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a> plus either FU or <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/121\" class=\"abstract_t\">121</a>]. Response rates (objective radiographic tumor regression or decreased urinary 5-hydroxyindoleacetic acid [5-HIAA]) were similar (33 and 26 percent FU and cyclophosphamide, respectively), as was survival. Toxicity was prominent in both regimens. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A subsequent ECOG trial increased the dosing interval between cycles of <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a><span class=\"nowrap\">/FU,</span> comparing this regimen with <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> alone [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/122\" class=\"abstract_t\">122</a>]. Although this <span class=\"nowrap\">streptozocin/FU</span> regimen was somewhat better tolerated than the one used in the earlier study, the response rate was similar to doxorubicin alone (22 versus 21 percent), as was survival. More recently, <span class=\"nowrap\">streptozocin/FU</span> was compared with <span class=\"nowrap\">doxorubicin/FU</span> in a randomized trial of 249 patients with advanced carcinoid [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/123\" class=\"abstract_t\">123</a>]. The radiographic response rate was similar with the two regimens (16 percent each), although there was a slight, but statistically significant, median survival benefit associated with <span class=\"nowrap\">streptozocin/FU</span> (24 versus 16 months). However, PFS was short (4.5 months), and over one-third of the patients receiving streptozocin developed mild to moderate renal toxicity.</p><p/><p>The relatively modest response rates of these regimens, together with the reported toxicity, have led many to question their utility in the routine treatment of patients with advanced gastrointestinal NETs [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/26\" class=\"abstract_t\">26</a>]. As such, they are rarely utilized in this setting.</p><p class=\"headingAnchor\" id=\"H190949005\"><span class=\"h2\">Dacarbazine and temozolomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In a Southwest Oncology Group study of 56 patients with metastatic GINETs receiving single agent <a href=\"topic.htm?path=dacarbazine-drug-information\" class=\"drug drug_general\">dacarbazine</a>, the overall tumor response rate was 16 percent [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/116\" class=\"abstract_t\">116</a>]. Toxicity was a concern; 88 percent of patients reported nausea <span class=\"nowrap\">and/or</span> vomiting. In another report of second-line dacarbazine following treatment with <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a><span class=\"nowrap\">/FU</span> or <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a><span class=\"nowrap\">/FU,</span> the response rate was only 8 percent [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/123\" class=\"abstract_t\">123</a>].</p><p><a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">Temozolomide</a> is an oral analog of <a href=\"topic.htm?path=dacarbazine-drug-information\" class=\"drug drug_general\">dacarbazine</a> that is generally better tolerated. Although temozolomide is active in pancreatic NETs, its single-agent activity appears more limited in GINETs. In a retrospective series that included 44 patients with GINETs, only one (2 percent) had an objective tumor response [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/124\" class=\"abstract_t\">124</a>]. The majority of these patients had primary GINETs. In contrast, 18 of 53 (34 percent) patients with pancreatic NETs had an objective response to treatment with temozolomide. </p><p>Several reports have suggested that <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">temozolomide</a> may be active in some patients with bronchial or thymic carcinoid tumors [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/125,126\" class=\"abstract_t\">125,126</a>]. However, a phase II study of temozolomide plus <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> reported no objective responses among 19 patients with advanced carcinoid, four of whom had bronchial carcinoids [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/127\" class=\"abstract_t\">127</a>]. (See <a href=\"topic.htm?path=lung-neuroendocrine-carcinoid-tumors-treatment-and-prognosis#H2421055611\" class=\"medical medical_review\">&quot;Lung neuroendocrine (carcinoid) tumors: Treatment and prognosis&quot;, section on 'Cytotoxic chemotherapy'</a>.)</p><p>Small studies have suggested activity for the combination of <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">temozolomide</a> and <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> in some GINETs: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one retrospective study of 18 patients with metastatic, well-differentiated NETs, there was one complete radiographic response and one partial response among four patients with GINET. Notably, one of the responses was in a patient with a duodenal NET [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/128\" class=\"abstract_t\">128</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a report of preliminary results from a phase II trial of <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> plus <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">temozolomide</a> presented at the 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, 4 of 12 patients with metastatic carcinoid originating in various sites were reported as having experienced partial responses [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/129\" class=\"abstract_t\">129</a>]. However, the primary sites of these tumors were not reported, and the trial had not yet completed full accrual. </p><p/><p>Larger, prospective studies are clearly needed to better assess the potential activity of <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">temozolomide</a> and <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> in GINETs and to assess whether activity may differ depending on primary tumor site.</p><p class=\"headingAnchor\" id=\"H190949012\"><span class=\"h3\">Oxaliplatin-based regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antitumor activity has been suggested for oxaliplatin-based combinations, although the total number of treated patients has been small. One combined analysis included data from two phase II trials totaling 76 patients with well-differentiated pancreatic NET (n = 28) or non-pancreatic NET (carcinoid cohort, n = 42), or poorly differentiated neuroendocrine carcinoma (n = 6) who were treated with <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a> plus <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> and either <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> (n = 40) or short-term infusional FU plus <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (n = 36) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/130\" class=\"abstract_t\">130</a>]. Overall, FOLFOX plus bevacizumab resulted in an objective response in 3 of 22 patients in the carcinoid cohort (14 percent, median PFS 19.3 months). Oxaliplatin plus capecitabine and bevacizumab was associated with an objective response in 1 of 20 patients (5 percent) and a median PFS of 19.1 months in the carcinoid cohort.</p><p>While these regimens may have activity in GINETs, the data are too limited to draw any conclusions as to the relative contributions of a fluoropyrimidine, <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a>, or <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>. </p><p class=\"headingAnchor\" id=\"H26472645\"><span class=\"h2\">Capecitabine plus bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Activity for <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> in combination with <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> was suggested in a multicenter phase II trial, in which 49 patients with progressive, metastatic GINETs (82 percent originating in small bowel, the remainder in the cecum, rectum, and stomach) received bevacizumab (7.5 <span class=\"nowrap\">mg/kg</span> every three weeks) with capecitabine (1000 <span class=\"nowrap\">mg/m<sup>2</sup></span> twice daily days 1 to 14 every 21 days) [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/131\" class=\"abstract_t\">131</a>]. The median treatment duration was 13.8 months. At 24 months maximum follow-up, the tumor control rate was 88 percent (partial response in 18 percent, stable disease in 70 percent), and the median PFS was 23.4 months. However, grade 3 or 4 treatment-related toxicity was experienced by 84 percent of patients, mainly digestive; 31 percent developed grade 3 or 4 hypertension.</p><p class=\"headingAnchor\" id=\"H1748382351\"><span class=\"h1\">IMMUNOTHERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The role of immunotherapy with immune checkpoint inhibitors is just beginning to be studied in patients with well-differentiated neuroendocrine tumors (NETs), and extremely limited data are available [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/132\" class=\"abstract_t\">132</a>]. However, trials are ongoing of several of these approaches in well-differentiated NETs [<a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/133-135\" class=\"abstract_t\">133-135</a>], and eligible patients should be encouraged to enroll. </p><p class=\"headingAnchor\" id=\"H190949140\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"headingAnchor\" id=\"H1974409\"><span class=\"h2\">Initial therapy</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Somatostatin analogs are highly effective in controlling the symptoms associated with advanced gastrointestinal neuroendocrine tumors (GINETs). For patients who are symptomatic from carcinoid syndrome, we recommend initiating treatment with a somatostatin analog alone rather than a combination of a somatostatin analog and interferon alfa (IFNa) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H190948921\" class=\"local\">'Somatostatin analogs'</a> above and <a href=\"#H190948949\" class=\"local\">'Interferon'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We also suggest initiating therapy with a somatostatin analog for patients who do not have carcinoid syndrome but who have somatostatin-receptor positive disease&nbsp;(as determined by diagnostic imaging with a radiolabeled somatostatin analog) and&nbsp;a high tumor burden (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring#H5\" class=\"medical medical_review\">&quot;Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring&quot;, section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with metastatic disease that appears completely resectable in the absence of extrahepatic metastases, diffuse bilobar involvement, or compromised liver function, we suggest resection rather than medical therapy (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H1974073\" class=\"local\">'General approach to the patient'</a> above and <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691406\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Surgical resection'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with asymptomatic, advanced, unresectable GINETs and small volume disease, we suggest observation alone rather than early administration of a somatostatin analog (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H190948935\" class=\"local\">'Control of tumor growth'</a> above and <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90693987\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Control of tumor growth'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H190949177\"><span class=\"h2\">Progressive disease</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with clinically meaningful tumor progression who are not already on a somatostatin analog, we suggest initiating treatment with a long-acting somatostatin analog (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Treatment with a long-acting somatostatin analog is also reasonable in patients with evidence of biochemical progression of disease with a rising urinary 5-hydroxyindoleacetic acid (5-HIAA) level, particularly if there is evidence of carcinoid heart disease. (See <a href=\"#H190948921\" class=\"local\">'Somatostatin analogs'</a> above and <a href=\"#H1648278982\" class=\"local\">'Carcinoid heart disease'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest hepatic arterial embolization, chemoembolization, or radioembolization rather than medical therapy alone as a palliative technique for symptomatic patients with hepatic-predominant unresectable disease (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H1974073\" class=\"local\">'General approach to the patient'</a> above and <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691449\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Hepatic artery embolization'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For most patients with a GINET and progressive disease despite a long-acting somatostatin analog who are not eligible for liver-directed therapy, we suggest <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a> rather than dose escalation of the long-acting somatostatin analog (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H168515048\" class=\"local\">'Everolimus'</a> above.)</p><p/><p class=\"bulletIndent1\">For patients with a somatostatin-receptor-positive GINET, treatment with peptide receptor radioligand therapy using a radiolabeled somatostatin analog such as <a href=\"topic.htm?path=lutetium-lu-177-dotatate-drug-information\" class=\"drug drug_general\">lutetium Lu-177 dotatate</a> (<sup>177</sup>Lu-Dotatate) is another reasonable option, either at the time of progression on the somatostatin analog or following progression on <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>, where it is available. There are no data specifically comparing <sup>177</sup>Lu-Dotatate with everolimus in patients progressing on long-acting somatostatin analog therapy, and the choice of therapy in this situation should be based upon the availability of <sup>177</sup>Lu-Dotatate and patient preference. (See <a href=\"#H86380627\" class=\"local\">'Radiolabeled somatostatin analogs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The place of IFNa in modern therapy for GINET is uncertain. IFNa may be an option for patients with advanced GINETs who have worsening symptoms or evidence of disease progression for whom there are no other treatment options. (See <a href=\"#H190948949\" class=\"local\">'Interferon'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The benefit of cytotoxic chemotherapy for advanced, low-grade GINETs continues to be debated. Regimens that have demonstrated evidence of activity in preliminary reports of phase II studies include <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a> plus short-term infusional <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a> plus <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (FOLFOX), and <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">temozolomide</a> plus <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a>; however, confirmatory studies are needed to better define the activity of these regimens and to assess whether response may differ depending on primary site. (See <a href=\"#H190948956\" class=\"local\">'Cytotoxic chemotherapy'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/1\" class=\"nounderline abstract_t\">Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.</a></li><li class=\"breakAll\">Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.</li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/3\" class=\"nounderline abstract_t\">Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21:1.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/4\" class=\"nounderline abstract_t\">Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/5\" class=\"nounderline abstract_t\">Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3:1335.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/6\" class=\"nounderline abstract_t\">Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/7\" class=\"nounderline abstract_t\">Riihim&auml;ki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139:2679.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/8\" class=\"nounderline abstract_t\">Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387:968.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/9\" class=\"nounderline abstract_t\">Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376:125.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/10\" class=\"nounderline abstract_t\">Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/11\" class=\"nounderline abstract_t\">Bousquet C, Lasfargues C, Chalabi M, et al. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab 2012; 97:727.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/12\" class=\"nounderline abstract_t\">Janson ET, Westlin JE, Eriksson B, et al. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994; 131:577.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/13\" class=\"nounderline abstract_t\">Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/14\" class=\"nounderline abstract_t\">di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77:402.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/15\" class=\"nounderline abstract_t\">Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 1991; 30:503.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/16\" class=\"nounderline abstract_t\">Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72:244.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/17\" class=\"nounderline abstract_t\">Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32:225.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/18\" class=\"nounderline abstract_t\">Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas 2011; 40:987.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/19\" class=\"nounderline abstract_t\">Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8:1041.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/20\" class=\"nounderline abstract_t\">Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39:279.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/21\" class=\"nounderline abstract_t\">Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/22\" class=\"nounderline abstract_t\">Toumpanakis C, Garland J, Marelli L, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther 2009; 30:733.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/23\" class=\"nounderline abstract_t\">Lamberts SW, de Herder WW, Krenning EP, Reubi JC. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. J Clin Endocrinol Metab 1994; 78:17.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/24\" class=\"nounderline abstract_t\">von Werder K, Losa M, M&uuml;ller OA, et al. Treatment of metastasising GRF-producing tumour with a long-acting somatostatin analogue. Lancet 1984; 2:282.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/25\" class=\"nounderline abstract_t\">Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61:6.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/26\" class=\"nounderline abstract_t\">Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/27\" class=\"nounderline abstract_t\">Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/28\" class=\"nounderline abstract_t\">Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol 2015; 21:1945.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/29\" class=\"nounderline abstract_t\">Woltering EA, Mamikunian PM, Zietz S, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas 2005; 31:392.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/30\" class=\"nounderline abstract_t\">O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88:770.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/31\" class=\"nounderline abstract_t\">Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80:244.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/32\" class=\"nounderline abstract_t\">Khan MS, El-Khouly F, Davies P, et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011; 34:235.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/33\" class=\"nounderline abstract_t\">Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/34\" class=\"nounderline abstract_t\">Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/35\" class=\"nounderline abstract_t\">Saif MW, Larson H, Kaley K, Shaib W. Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect. Expert Opin Drug Saf 2010; 9:867.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/36\" class=\"nounderline abstract_t\">Vaughan DJ, Brunner MD. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 1997; 35:129.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/37\" class=\"nounderline abstract_t\">Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90:227.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/38\" class=\"nounderline abstract_t\">Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42:557.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/39\" class=\"nounderline abstract_t\">Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002; 79:180.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/40\" class=\"nounderline abstract_t\">Imtiaz KE, Monteith P, Khaleeli A. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clin Endocrinol (Oxf) 2000; 53:755.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/41\" class=\"nounderline abstract_t\">Rinke A, M&uuml;ller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/42\" class=\"nounderline abstract_t\">Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37:1014.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/43\" class=\"nounderline abstract_t\">Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16:2963.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/44\" class=\"nounderline abstract_t\">Sid&eacute;ris L, Dub&eacute; P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 2012; 17:747.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/45\" class=\"nounderline abstract_t\">Faiss S, Pape UF, B&ouml;hmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/46\" class=\"nounderline abstract_t\">Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95:3276.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/47\" class=\"nounderline abstract_t\">Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23:412.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/48\" class=\"nounderline abstract_t\">Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000; 14:557.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/49\" class=\"nounderline abstract_t\">Caplin ME, Pavel M, &#262;wik&#322;a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371:224.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/50\" class=\"nounderline abstract_t\">Michael M, Garcia-Carbonero R, Weber MM, et al. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist 2017; 22:272.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/51\" class=\"nounderline abstract_t\">Ter-Minassian M, Zhang S, Brooks NV, et al. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors. Oncologist 2017; 22:165.</a></li><li class=\"breakAll\">Arnold R, Wittenberg M, Rinke A, et al. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival (abstract). J Clin Oncol 31, 2013 (suppl; abstr 4030). http://meetinglibrary.asco.org/content/115200-132 (Accessed on June 27, 2013).</li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/53\" class=\"nounderline abstract_t\">Faiss S, R&auml;th U, Mansmann U, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999; 60:469.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/54\" class=\"nounderline abstract_t\">Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004; 151:107.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/55\" class=\"nounderline abstract_t\">Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992; 3:35.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/56\" class=\"nounderline abstract_t\">Detjen KM, Welzel M, Farwig K, et al. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 2000; 118:735.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/57\" class=\"nounderline abstract_t\">Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004; 80 Suppl 1:85.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/58\" class=\"nounderline abstract_t\">Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309:129.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/59\" class=\"nounderline abstract_t\">Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001; 12:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/60\" class=\"nounderline abstract_t\">Sch&ouml;ber C, Schmoll E, Schmoll HJ, et al. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. Eur J Cancer 1992; 28A:1664.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/61\" class=\"nounderline abstract_t\">Biesma B, Willemse PH, Mulder NH, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer 1992; 66:850.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/62\" class=\"nounderline abstract_t\">Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 1993; 72:3099.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/63\" class=\"nounderline abstract_t\">Dirix LY, Vermeulen PB, Fierens H, et al. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect? Anticancer Drugs 1996; 7:175.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/64\" class=\"nounderline abstract_t\">Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 1989; 7:865.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/65\" class=\"nounderline abstract_t\">Hanssen LE, Schrumpf E, Kolbenstvedt AN, et al. Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989; 24:787.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/66\" class=\"nounderline abstract_t\">Creutzfeldt W, Bartsch HH, Jacubaschke U, St&ouml;ckmann F. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol 1991; 30:529.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/67\" class=\"nounderline abstract_t\">Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol 1991; 79 Suppl 1:74.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/68\" class=\"nounderline abstract_t\">Joensuu H, Kumpulainen E, Gr&ouml;hn P. Treatment of metastatic carcinoid tumour with recombinant interferon alfa. Eur J Cancer 1992; 28A:1650.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/69\" class=\"nounderline abstract_t\">Janson ET, R&ouml;nnblom L, Ahlstr&ouml;m H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992; 3:635.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/70\" class=\"nounderline abstract_t\">Doberauer C, Niederle N, Kloke O, et al. [Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon]. Onkologie 1987; 10:340.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/71\" class=\"nounderline abstract_t\">Pavel M, Kidd M, Modlin I. Systemic therapeutic options for carcinoid. Semin Oncol 2013; 40:84.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/72\" class=\"nounderline abstract_t\">V&auml;lim&auml;ki M, J&auml;rvinen H, Salmela P, et al. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991; 67:547.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/73\" class=\"nounderline abstract_t\">Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26:1316.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/74\" class=\"nounderline abstract_t\">Pavel ME, Baum U, Hahn EG, et al. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 2006; 26:8.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/75\" class=\"nounderline abstract_t\">K&ouml;lby L, Persson G, Franz&eacute;n S, Ahr&eacute;n B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90:687.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/76\" class=\"nounderline abstract_t\">Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3:761.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/77\" class=\"nounderline abstract_t\">Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28:245.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/78\" class=\"nounderline abstract_t\">Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/79\" class=\"nounderline abstract_t\">Oh DY, Kim TW, Park YS, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 2012; 118:6162.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/80\" class=\"nounderline abstract_t\">Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005.</a></li><li class=\"breakAll\">Yao JC, Hainsworth JD, Wolin EM, et al. Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus or placebo among patients with advanced neuroendocrine tumors (abstract). J Clin Oncol 2012; 30 (sauppl 4): abstract 157. Abstract available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=88080 (Accessed on March 16, 2012).</li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/82\" class=\"nounderline abstract_t\">Pavel ME, Baudin E, &Ouml;berg KE, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol 2017; 28:1569.</a></li><li class=\"breakAll\">Yao J, Fazio N, Singh S, et al. Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study (abstract). J Clin Oncol 34, 2016 (suppl; abstr 4090). Abstract available online at http://meetinglibrary.asco.org/content/164832-176 (Accessed on June 09, 2016).</li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/84\" class=\"nounderline abstract_t\">Pavel ME, Singh S, Strosberg JR, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18:1411.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/85\" class=\"nounderline abstract_t\">Yao JC, Guthrie KA, Moran C, et al. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 2017; :JCO2016704072.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/86\" class=\"nounderline abstract_t\">McCarthy KE, Woltering EA, Espenan GD, et al. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998; 4:94.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/87\" class=\"nounderline abstract_t\">Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003; 44:1.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/88\" class=\"nounderline abstract_t\">Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32:123.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/89\" class=\"nounderline abstract_t\">McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237:718.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/90\" class=\"nounderline abstract_t\">Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43:610.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/91\" class=\"nounderline abstract_t\">Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003; 30:417.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/92\" class=\"nounderline abstract_t\">Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/93\" class=\"nounderline abstract_t\">Grozinsky-Glasberg S, Barak D, Fraenkel M, et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011; 117:1377.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/94\" class=\"nounderline abstract_t\">Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/95\" class=\"nounderline abstract_t\">Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012; 30:1100.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/96\" class=\"nounderline abstract_t\">Savelli G, Bertagna F, Franco F, et al. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide. Cancer 2012; 118:2915.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/97\" class=\"nounderline abstract_t\">Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2:S186.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/98\" class=\"nounderline abstract_t\">Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/99\" class=\"nounderline abstract_t\">Paganelli G, Bodei L, Handkiewicz Junak D, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002; 66:393.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/100\" class=\"nounderline abstract_t\">Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36:147.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/101\" class=\"nounderline abstract_t\">Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29:2416.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/102\" class=\"nounderline abstract_t\">H&ouml;rsch D, Ezziddin S, Haug A, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer 2016; 58:41.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/103\" class=\"nounderline abstract_t\">Brabander T, Van der Zwan WA, Teunissen JJ, et al. Long-term efficacy, survival and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/104\" class=\"nounderline abstract_t\">Bergsma H, van Lom K, Raaijmakers MHGP, et al. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med 2018; 59:452.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/105\" class=\"nounderline abstract_t\">Bergsma H, Konijnenberg MW, van der Zwan WA, et al. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging 2016; 43:1802.</a></li><li class=\"breakAll\">FDA approval announcement for lutetium Lu 177 dotatate available online at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm (Accessed on January 29, 2018).</li><li class=\"breakAll\">Prescribing information for lutetium Lu 177 dotatate available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf?et_cid=39972490&amp;et_rid=907466112&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f208700s000lbl.pdf (Accessed on January 29, 2018).</li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/108\" class=\"nounderline abstract_t\">Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017; 105:295.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/109\" class=\"nounderline abstract_t\">Sywak MS, Pasieka JL, McEwan A, et al. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg 2004; 28:1157.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/110\" class=\"nounderline abstract_t\">Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004; 101:1987.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/111\" class=\"nounderline abstract_t\">Kennedy A, Coldwell D, Sangro B, et al. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol 2012; 35:393.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/112\" class=\"nounderline abstract_t\">Nwosu AC, Jones L, Vora J, et al. Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 2008; 98:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/113\" class=\"nounderline abstract_t\">Taal BG, Hoefnagel CA, Valdes Olmos RA, et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996; 14:1829.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/114\" class=\"nounderline abstract_t\">Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/115\" class=\"nounderline abstract_t\">Medley L, Morel AN, Farrugia D, et al. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 2011; 104:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/116\" class=\"nounderline abstract_t\">Bukowski RM, Tangen CM, Peterson RF, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994; 73:1505.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/117\" class=\"nounderline abstract_t\">Ansell SM, Pitot HC, Burch PA, et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91:1543.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/118\" class=\"nounderline abstract_t\">Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 2004; 22:353.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/119\" class=\"nounderline abstract_t\">Kulke MH, Kim H, Clark JW, et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004; 101:934.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/120\" class=\"nounderline abstract_t\">Ansell SM, Mahoney MR, Green EM, Rubin J. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol 2004; 27:232.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/121\" class=\"nounderline abstract_t\">Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2:327.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/122\" class=\"nounderline abstract_t\">Engstrom PF, Lavin PT, Moertel CG, et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984; 2:1255.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/123\" class=\"nounderline abstract_t\">Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23:4897.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/124\" class=\"nounderline abstract_t\">Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009; 15:338.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/125\" class=\"nounderline abstract_t\">Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13:2986.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/126\" class=\"nounderline abstract_t\">Crona J, Fanola I, Lindholm DP, et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 2013; 98:151.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/127\" class=\"nounderline abstract_t\">Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30:2963.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/128\" class=\"nounderline abstract_t\">Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013; 71:663.</a></li><li class=\"breakAll\">Fine, RL, Gulati AP, Tsushima D, et al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumor (abstract 179). J Clin Oncol 32, 2014 (suppl 3; abstr 179). http://meetinglibrary.asco.org/content/122616-143 (Accessed on March 02, 2014).</li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/130\" class=\"nounderline abstract_t\">Kunz PL, Balise RR, Fehrenbacher L, et al. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas 2016; 45:1394.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/131\" class=\"nounderline abstract_t\">Mitry E, Walter T, Baudin E, et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial. Eur J Cancer 2014; 50:3107.</a></li><li><a href=\"https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion/abstract/132\" class=\"nounderline abstract_t\">Chauhan A, Anthony L. Immune oncology and neuroendocrine tumors. Ann Oncol 2017; 28:2322.</a></li><li class=\"breakAll\">https://clinicaltrials.gov/ct2/show/NCT02955069?term=02955069&amp;rank=1.</li><li class=\"breakAll\">https://clinicaltrials.gov/ct2/show/NCT03074513?term=03074513&amp;rank=1.</li><li class=\"breakAll\">https://clinicaltrials.gov/ct2/show/NCT03043664?term=03043664&amp;rank=1.</li></ol></div><div id=\"topicVersionRevision\">Topic 16901 Version 45.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H190949140\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H190948900\" id=\"outline-link-H190948900\">INTRODUCTION</a></li><li><a href=\"#H1973644\" id=\"outline-link-H1973644\">CLASSIFICATION, BIOLOGIC BEHAVIOR, AND IMPLICATIONS FOR TREATMENT</a></li><li><a href=\"#H1974073\" id=\"outline-link-H1974073\">GENERAL APPROACH TO THE PATIENT</a></li><li><a href=\"#H190948921\" id=\"outline-link-H190948921\">SOMATOSTATIN ANALOGS</a><ul><li><a href=\"#H447989550\" id=\"outline-link-H447989550\">Patients with symptoms from hormone hypersecretion</a><ul><li><a href=\"#H541868112\" id=\"outline-link-H541868112\">- Dosing</a></li><li><a href=\"#H541868118\" id=\"outline-link-H541868118\">- Side effects</a></li><li><a href=\"#H447989628\" id=\"outline-link-H447989628\">- Prevention and management of carcinoid crisis</a></li></ul></li><li><a href=\"#H1648278982\" id=\"outline-link-H1648278982\">Carcinoid heart disease</a></li><li><a href=\"#H190948935\" id=\"outline-link-H190948935\">Control of tumor growth</a></li></ul></li><li><a href=\"#H190948949\" id=\"outline-link-H190948949\">INTERFERON</a><ul><li><a href=\"#H447989844\" id=\"outline-link-H447989844\">IFNa plus a somatostatin analog</a></li></ul></li><li><a href=\"#H168515036\" id=\"outline-link-H168515036\">MOLECULARLY TARGETED THERAPY</a><ul><li><a href=\"#H168515048\" id=\"outline-link-H168515048\">Everolimus</a></li><li><a href=\"#H447989880\" id=\"outline-link-H447989880\">Small molecule TK inhibitors</a></li><li><a href=\"#H168515075\" id=\"outline-link-H168515075\">Bevacizumab</a></li></ul></li><li><a href=\"#H86380552\" id=\"outline-link-H86380552\">PEPTIDE RECEPTOR RADIOLIGAND THERAPY</a><ul><li><a href=\"#H86380627\" id=\"outline-link-H86380627\">Radiolabeled somatostatin analogs</a><ul><li><a href=\"#H545183865\" id=\"outline-link-H545183865\">- Yttrium-90 dotatoc</a></li><li><a href=\"#H1264345288\" id=\"outline-link-H1264345288\">- Lutetium Lu-177 dotatate</a></li></ul></li><li><a href=\"#H86381166\" id=\"outline-link-H86381166\">MIBG</a></li></ul></li><li><a href=\"#H190948956\" id=\"outline-link-H190948956\">CYTOTOXIC CHEMOTHERAPY</a><ul><li><a href=\"#H190949005\" id=\"outline-link-H190949005\">Dacarbazine and temozolomide</a><ul><li><a href=\"#H190949012\" id=\"outline-link-H190949012\">- Oxaliplatin-based regimens</a></li></ul></li><li><a href=\"#H26472645\" id=\"outline-link-H26472645\">Capecitabine plus bevacizumab</a></li></ul></li><li><a href=\"#H1748382351\" id=\"outline-link-H1748382351\">IMMUNOTHERAPY</a></li><li><a href=\"#H190949140\" id=\"outline-link-H190949140\">SUMMARY AND RECOMMENDATIONS</a><ul><li><a href=\"#H1974409\" id=\"outline-link-H1974409\">Initial therapy</a></li><li><a href=\"#H190949177\" id=\"outline-link-H190949177\">Progressive disease</a></li></ul></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/16901|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=ONC/104426\" class=\"graphic graphic_algorithm\">- Approach to metastatic GINET</a></li></ul></li><li><div id=\"ONC/16901|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/74630\" class=\"graphic graphic_picture\">- Histologic appearance of neuroendocrine tumors</a></li></ul></li><li><div id=\"ONC/16901|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/60365\" class=\"graphic graphic_table\">- Classification of neuroendocrine neoplasms GI tract</a></li><li><a href=\"image.htm?imageKey=ENDO/79329\" class=\"graphic graphic_table\">- Products of well-differentiated neuroendocrine tumors</a></li><li><a href=\"image.htm?imageKey=ONC/74693\" class=\"graphic graphic_table\">- RECIST response criteria solid tumors</a></li><li><a href=\"image.htm?imageKey=ONC/90847\" class=\"graphic graphic_table\">- Trials of novel agents in advanced carcinoid tumors</a></li><li><a href=\"image.htm?imageKey=ONC/116972\" class=\"graphic graphic_table\">- Inclusion criteria for peptide receptor radionuclide therapy</a></li><li><a href=\"image.htm?imageKey=ONC/52299\" class=\"graphic graphic_table\">- Chemo met carcinoid</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=carcinoid-heart-disease\" class=\"medical medical_review\">Carcinoid heart disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-characteristics-of-well-differentiated-neuroendocrine-carcinoid-tumors-arising-in-the-tubular-digestive-tract-lung-and-genitourinary-tract\" class=\"medical medical_review\">Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the tubular digestive tract, lung, and genitourinary tract</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-of-the-carcinoid-syndrome\" class=\"medical medical_review\">Clinical features of the carcinoid syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-the-carcinoid-syndrome-and-tumor-localization\" class=\"medical medical_review\">Diagnosis of the carcinoid syndrome and tumor localization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extensive-stage-small-cell-lung-cancer-initial-management\" class=\"medical medical_review\">Extensive stage small cell lung cancer: Initial management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-grade-gastroenteropancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">High-grade gastroenteropancreatic neuroendocrine neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lung-neuroendocrine-carcinoid-tumors-treatment-and-prognosis\" class=\"medical medical_review\">Lung neuroendocrine (carcinoid) tumors: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring\" class=\"medical medical_review\">Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neuroendocrine-neoplasms-of-unknown-primary-site\" class=\"medical medical_review\">Neuroendocrine neoplasms of unknown primary site</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system\" class=\"medical medical_review\">Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staging-treatment-and-posttreatment-surveillance-of-nonmetastatic-well-differentiated-gastrointestinal-tract-neuroendocrine-carcinoid-tumors\" class=\"medical medical_review\">Staging, treatment, and posttreatment surveillance of nonmetastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thymic-neuroendocrine-carcinoid-tumors\" class=\"medical medical_review\">Thymic neuroendocrine (carcinoid) tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-the-carcinoid-syndrome\" class=\"medical medical_review\">Treatment of the carcinoid syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis</a></li></ul></div></div>","javascript":null}